A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

NCT03816631 | Completed Phase 1

• 3 other identifiers: CR1085712018-002817-3663623872FLZ1013
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose is to evaluate the pharmacokinetics (PK) of a single oral dose of 600 milligram (mg) pimodivir in adult participants with impaired hepatic function compared to adult participants with normal hepatic function.

Conditions

Hepatic Impairment

Outcome Measures

Primary Outcomes (3)

• Maximum Observed Analyte Concentration (Cmax) of Pimodivir

  Cmax is defined as maximum observed analyte concentration of pimodivir.

  Predose, 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120 hours post dose and end of study (up to Day 14)

• Area Under Concentration-Time Curve from Time 0 to the Time of the Last Concentration (AUC[last]) of Pimodivir

  AUC(last) is defined as the time 0 to the time of the last measurable (non-below quantification limit) concentration of Pimodivir calculated by linear-linear trapezoidal summation.

  Predose, 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120 hours post dose and end of study (up to Day 14)

• Area Under Concentration-Time Curve from Time 0 to Infinite Time (AUC[0-infinity]) of Pimodivir

  The AUC (\[0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C (last)/ lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to the time of the last measurable concentration, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

  Predose, 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120 hours post dose and end of study (up to Day 14)

Secondary Outcomes (1)

• Number of Participants with Adverse Event as a Measure of Safety and Tolerability

  Approximately 42 days

Study Arms (4)

Part A: Group 1: Severe hepatic function

EXPERIMENTAL

Participants with severe hepatic function will receive single oral dose of pimodivir 600 milligram (mg) (2\*300 mg tablet) under fasted condition on Day 1.

Drug: Pimodivir

Part A and B: Group 2: Normal hepatic function

EXPERIMENTAL

Participants with normal hepatic function will receive single oral dose of pimodivir 600 mg (2\*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.

Drug: Pimodivir

Part B: Group 3: Moderate hepatic function

EXPERIMENTAL

Participants with moderate hepatic function will receive single oral dose of pimodivir 600 mg (2\*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.

Drug: Pimodivir

Part B: Group 4: Mild hepatic function

EXPERIMENTAL

Participants with mild hepatic function will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.

Drug: Pimodivir

Interventions

Pimodivir DRUG

Participants will receive single oral dose of Pimodivir 600 mg (2\*300 mg tablets) under fasted condition on Day 1.

Also known as: JNJ-63623872

Part A and B: Group 2: Normal hepatic function; Part A: Group 1: Severe hepatic function; Part B: Group 3: Moderate hepatic function; Part B: Group 4: Mild hepatic function

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must have a stable hepatic function as confirmed by albumin levels, prothrombin time (PT), International Normalized Ratio (INR), and platelet count measured during screening and those measured within 24 hours prior to study drug administration. Participants with a Transjugular Intrahepatic Portosystemic Shunt procedure will be allowed to participate in the study
• Participant must have a body mass index (BMI; weight \[Kilogram {kg}/height\^2 \[meter {m}\^2\]) between 18.0 and 38.0 kg/m\^2, extremes included, and body weight not less than 50 kg at screening
• Participant must have a 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and function at screening, including: (a) Sinus rhythm; (b) Pulse rate between 45 and 100 beats per minute (bpm); (c) QT interval corrected for heart rate (QTc) according to Fridericia formula (QTcF) less than or equal to (\<=) 450 millisecond (ms) for male participant and \<= 470 ms for female participant; (d) QRS interval of less than (\<) 120 ms; (e) PR interval \<= 220 ms and (f) Electrocardiogram morphology consistent with healthy cardiac conduction and function. Participant with pacemaker is eligible as long as all criteria mentioned above are met
• A woman, except if postmenopausal, must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin \[beta-hCG\]) at screening and a negative urine pregnancy test on Day -1
• Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies

You may not qualify if:

• Participant has known allergies, hypersensitivity, or intolerance to pimodivir or its excipients
• Participant has donated blood or blood products or had substantial loss of blood (more than 500 milliliter \[mL\]) within 3 months before administration of the study drug or intention to donate blood or blood products during the study
• Participant has received an experimental drug (including investigational vaccines) or used an experimental medical device within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before administration of the study drug is scheduled
• Participant has preplanned surgery or procedures that would interfere with the conduct of the study
• Participant is a woman who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or a woman of childbearing potential who is unwilling to use an acceptable method of contraception

Sponsors & Collaborators

• Janssen-Cilag International NV: lead

Study Sites (2)

CRS Clinical Research Services Kiel GmbH

Kiel, 24105, Germany

Location

APEX GmbH

München, 81241, Germany

Location

MeSH Terms

Interventions

pimodivir

Study Officials

• Janssen-Cilag International NV Clinical Trial

  Janssen-Cilag International NV

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2019
• First Posted: January 25, 2019
• Study Start: May 28, 2019
• Primary Completion: April 27, 2020
• Study Completion: April 27, 2020
• Last Updated: February 3, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will share

Locations

DE (2)